China
Africa
Explore chapters and articles related to this topic
Cancer
Published in Rachael E. Docking, Jennifer Stock, International Handbook of Positive Aging, 2017
Michelle Lycke, Lies Pottel, Tom Boterberg, Supriya G. Mohile, Etienne Brain, Philip R. Debruyne
The pioneers and landmark actions led around CGA by Silvio Monfardini, Lodovico Balducci, Matti Aapro, Jean Pierre Droz and many others (Monfardini et al., 1996; Monfardini and Balducci, 1999; Repetto et al., 2002; Terret, Albrand and Droz, 2004; Extermann et al., 2005) were a real dawning eye-opener for the community of healthcare givers. However, around the twenty-first century, despite growing evidence that geriatric oncology would become a key component in the daily oncology practice, interest in geriatric oncology within the oncology world remained arduous. As a result, for those who were already involved in the management of elderly cancer patients and who underlined its importance, the International Society of Geriatric Oncology or Société Internationale d’Onco Gériatrie (SIOG) was launched in 2000. Since then, SIOG has deeply committed to supporting research linking aging and cancer, developing education and expanding international outreach and dimension, as summarized in its ten priorities (www.siog.org).
Is there a worthwhile value in personalizing radiation therapy for breast cancer patients? Time for a new paradigm in the older adult population
Published in Expert Review of Precision Medicine and Drug Development, 2021
Viola Salvestrini, Matteo Mariotti, Marco Banini, Carlotta Becherini, Luca Visani, Vieri Scotti, Isacco Desideri, Lorenzo Livi, Icro Meattini
Over the past few decades, the world population has increased dramatically including a large number of elderly people. This explosion in population aging comes with a rising number of older adults who have potential multiple comorbidities and chronic illnesses, including cancer. Indeed, the prevalence of multimorbidity in older patients ranges from 55 to 98% [1]. Older cancer population represents a major public health issue and tailoring of treatment for these patients represents a paradigmatic example of treatment optimization. The number of elderly living with cancer disease is high due to the possibility of early diagnosis in the last years and the recent advances in cancer treatment strategy. Breast cancer is the most common malignancy among women, and it is estimated that around 20% of newly diagnosed patients will be aged more than 70 years. It has been widely reported that breast cancer-related mortality increases with age, regardless of disease stage. A specific management for this elder population is not defined because clinical trials usually do not include this subset of patients. The International Society of Geriatric Oncology in conjunction with the European Society of Breast Cancer Specialists recommended that any decision to treat cancer in the older adult woman with cancer must be individual and based on specific evaluation of the elderly woman and cancer.
Approved and emerging treatments of malignant pleural mesothelioma in elderly patients
Published in Expert Review of Respiratory Medicine, 2019
Giovanni Luca Ceresoli, Antonio Rossi
The incidence of MPM is rapidly growing in the elderly population, as reported by several epidemiological studies and mesothelioma registers in industrialized countries. However, although geriatric oncology has been accepted for many years as a defined field of clinical activity and research, elderly patients with relatively rare tumors such as MPM are under-represented in clinical trials. Therefore, there are no specific guidelines for diagnostic and therapeutic management of this patient population. Clinical uncertainty results in a case by case evaluation, which can lead to suboptimal or excessively toxic treatments, and poorer outcomes as compared with younger cases. Lack of expertise or low volume referral of elderly with MPM may favor a nihilistic attitude toward these patients.
Pharmacotherapeutic considerations for elderly patients with colorectal cancer
Published in Expert Opinion on Pharmacotherapy, 2019
Age is a well-known dominant cancer risk [1,2]. Those ≥65 years old (yo) are generally classified as elderly [3]. The American Society of Clinical Oncology (ASCO) states that ~70% diagnosed with cancer are elderly, and starting at age 70 yo, the cancer lifetime probability is 1:3 men and 1:4 women [1]. The elderly is a growing demographic; population estimates predict by 2030 that ~20% of the US population will be ≥65 yo [4–6], and those >79 yo are expected to increase over the next two decades [4]. Worldwide, those ≥60 yo will represent ~20% of the world’s population by 2050 [7]. As life expectancy increases, cancer incidence in the elderly will continue to climb [1,2,8]. Given these factors, there is a critical need to elucidate geriatric oncology intricacies as they relate to specific malignancies.